Since 1962, NIAID’s Vaccine and Treatment Evaluation Units (VTEUs) have played a vital role in NIAID’s efforts to develop new and improved vaccines and treatments to combat emerging and re-emerging infectious diseases. Currently, there are nine VTEUs based in the United States. Every seven years, NIAID competitively renews its funding of the VTEUs. For the fiscal year 2020 awards, NIAID envisions some changes to the VTEU structure to both allow for efficient implementation of clinical trial protocols and to create a leadership group and operations center that will be central to carrying out NIAID’s infectious disease clinical trial priorities.
To learn more about NIAID’s vision for its VTEU structure, please watch this video presentation by DMID Director Emily Erbelding, M.D., M.P.H.